AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for January 11, 2017 meeting

IV. Secretary’s report

V. Old Business
   A. MCO responses to Miralax® (Amerigroup/WellCare)
   B. Protocols review and streamlining
   C. Smoking cessation therapy processes report
   D. Proposed educational newsletter: “Using Naloxone to Prevent Drug Overdose Deaths”

VI. New Business
   A. Proposed protocol for safe and efficient use of eteplirsen (Exondys 51®)
   B. Clarification of brand name prescription drug policy for behavior health patients

VII. Informational Highlights/Reports
    2. Summary of DURB Action Items
    3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
       (b) Physician-administered drugs by amount paid/category
    4. Medication information:
       (a) New Jersey Enacts Strict Opioid Prescribing Law
       (b) FDA approves first treatment for frequent urination at night due to overproduction of urine
       (c) Georgia bill would hold providers criminally liable for not tracking opioid prescriptions
       (d) Drug Overdose Deaths in the United States, 1999-2015
       (e) Gouging the elderly: Number of US seniors on multiple psychotropic drugs doubles over decade